Screening fOR Throat Cancer (SORT)
SORT (Screening fOR Throat Cancer)
This study will screen people for biomarkers of Human Papillomavirus (HPV) to form a cohort of people who may be at increased risk of HPV-oropharyngeal cancer (HPV-OPC). The investigators will follow these individuals prospectively to evaluate risk for OPC.
Studieoversikt
Status
Status
Forhold
Forhold
Detaljert beskrivelse
This study will assess HPV16 biomarkers, including serum HPV16 E6 antibodies, plasma and oral HPV16 DNA, and ultrasound, to understand the feasibility and utility of HPV16 biomarker screening to identify those at increased risk of HPV-OPC. This study will screen approximately 2500 people. The focus of the study is to determine whether sequential testing for oral and plasma HPV16 DNA, among those with HPV16 E6 antibodies, improves identification of persistent HPV16 biomarkers indicative of preclinical HPV-OPC and HPV-OPC compared to standalone testing with HPV16 E6 antibodies among people with and without HIV. The study includes community screening, as well as biobank screening with longitudinal follow-up of those who screen positive.
Study Design Overview: This study has an initial screen that includes two populations: screening of biobank samples "biobank group" and screening of healthy members of the community "community group" which can be done via an in-person visit or via remote sample collection. The subset of participants with HPV16 biomarkers detected will be asked to join the longitudinal follow-up. During follow-up, participants will have more samples collected and have a neck ultrasound to look for any precancerous lesions.
The study is led by Dr. Amber D'Souza and Dr. Carole Fakhry (Johns Hopkins). Participants are being enrolled from the MWCCS cohort, from Baltimore, MD, and across the US. If interested, complete the study eligibility form at [link coming] or email hpv@jhu.edu with questions.
Studietype
Studietype
Registrering (Antatt)
Registrering
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Amber D'Souza, PhD
- Telefonnummer: 410-502-2583
- E-post: gdsouza2@jhu.edu
Studiesteder
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21205
- Johns Hopkins Hospital
-
Ta kontakt med:
- Amber D'Souza, PhD
- Telefonnummer: 410-502-2583
- E-post: gdsouza2@jhu.edu
-
Hovedetterforsker:
- Amber D'Souza, PhD
-
Hovedetterforsker:
- Carole Fakhry, MD, MPH
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
The study population will be drawn from multiple sources, including healthy men from the broader U.S. population interested in the study via online self-referral, website outreach, or study outreach, as well as participants from the MACS WIHS Combined Cohort Study (MWCCS).
Beskrivelse
Inclusion Criteria:
- Part I: Participants in Screening
To be eligible to participate in Part I of this study, an individual must meet the following criteria:
Community and Internet Screen eligibility:
- Male, 40-69 years old
- Willing to self-collect or come in person to collect screening biospecimens
- Willing to be contacted to arrange follow-up visits, if determined to be eligible for follow-up
- Ability to understand and the willingness to sign a written informed consent document
Biorepository Screen eligibility:
-
Male, 40-69 years old
-
Active participant within MWCCS
-
Willing to be contacted to arrange follow-up visits, if determined to be eligible for follow-up
-
Ability to understand and the willingness to sign a written informed consent document
- Part II: Participants in Follow-Up
To be eligible to participate in Part II of this study, an individual must meet all of the following criteria:
- HPV16 biomarker detected in Part I screen
- Willingness to complete annual follow-up visits
Exclusion Criteria:
- Part I: Participants in Screening
An individual who meets any of the following criteria will be excluded from participation in this study:
-
Presence of medical or psychiatric condition affecting ability to give voluntary, informed consent.
-
Participants who do not speak English cannot enroll because the consent and study survey are only available in English. However, if there is a hearing, literacy, or minor fluency issue and the participant requests assistance from a family member or the study coordinator, this individual may still enroll and receive this assistance to ensure the participant fully hears and understands everything being asked.
-
History of head and neck cancer
- Part II: Participants in Follow-Up
An individual who meets any of the following criteria will be excluded from participation in this part of the study:
• Unable to complete annual follow-up visits
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Antall grupper / kohorter
Kohorter og intervensjoner
Gruppe / KohortGruppe / Kohort |
|---|
|
Prospective Observational Cohort
Prospective cohort of adult male participants from two groups: community group (see eligibility form) an biobank group (enrolled from MWCCS cohort). Both groups will undergo initial screening, with eligible participants continuing onto follow-up testing, which may include blood collection, oral rinse collection, anal Pap smear, ultrasound imaging, and surveys. |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
HPV16 E6 antibodies present or absent in serum sample
Tidsramme: Baseline to end of three-year follow-up
|
To determine whether sequential testing for oral or plasma HPV16 DNA, among those with HPV16 E6 antibodies, improves identification of persistent HPV16 biomarkers indicative of preclinical HPV-OPC and HPV-OPC compared to standalone testing with HPV16 E6 antibodies. |
Baseline to end of three-year follow-up
|
|
Oral HPV16 DNA present or absent
Tidsramme: Baseline to end of three-year follow-up
|
To determine whether sequential testing for oral HPV16 DNA, among those with HPV16 E6 antibodies, improves identification of persistent HPV16 biomarkers indicative of preclinical HPV-OPC and HPV-OPC compared to standalone testing with HPV16 E6 antibodies. |
Baseline to end of three-year follow-up
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Feasibility of community screening
Tidsramme: Baseline to end of three-year follow-up
|
To assess whether primary screening in a community setting of healthy individuals can lead to at least 80% of those with HPV16 E6 antibodies identified agreeing to complete follow-up biomarker collection and ultrasound for secondary screening. |
Baseline to end of three-year follow-up
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Samarbeidspartnere
Samarbeidspartnere
Publikasjoner og nyttige lenker
Generelle publikasjoner
- D'Souza G, Tewari SR, Troy T, Waterboer T, Struijk L, Castillo R, Wright H, Shen M, Miles B, Johansson M, Robbins HA, Fakhry C. Prevalence of oral and blood oncogenic human papillomavirus biomarkers among an enriched screening population: Baseline results of the MOUTH study. Cancer. 2023 Aug 1;129(15):2373-2384. doi: 10.1002/cncr.34783. Epub 2023 Apr 9.
- Scott-Wittenborn N, D'Souza G, Tewari S, Rooper L, Troy T, Drake V, Bigelow EO, Windon MJ, Ryan WR, Ha PK, Kiess AP, Miles B, Westra WH, Mydlarz WK, Eisele DW, Fakhry C. Prevalence of human papillomavirus in head and neck cancers at tertiary care centers in the United States over time. Cancer. 2022 May 1;128(9):1767-1774. doi: 10.1002/cncr.34124. Epub 2022 Feb 8.
- Scott-Wittenborn N, D'Souza G, Aygun N, Tewari SR, Azadi J, Vosler P, Gooi Z, Mehta V, Mydlarz W, Nance M, Mlot S, Patel MR, Tan M, Miles BA, Troy T, Fakhry C. Feasibility of clinical evaluation of individuals with increased risk for HPV-associated oropharynx cancer. Head Neck. 2023 Jan;45(1):95-102. doi: 10.1002/hed.27212. Epub 2022 Oct 6.
- Tewari SR, D'Souza G, Troy T, Wright H, Struijk L, Waterboer T, Fakhry C. Association of Plasma Circulating Tumor HPV DNA With HPV-Related Oropharynx Cancer. JAMA Otolaryngol Head Neck Surg. 2022 May 1;148(5):488-489. doi: 10.1001/jamaoto.2022.0159.
- D'Souza G, Tewari SR, Troy T, Webster-Cyriaque J, Wiley DJ, Lahiri CD, Palella FJ, Gillison ML, Strickler HD, Struijk L, Waterboer T, Ho K, Kwait J, Lazar J, Weber KM, Fakhry C. Oncogenic Oral Human Papillomavirus Clearance Patterns over 10 Years. Cancer Epidemiol Biomarkers Prev. 2024 Apr 3;33(4):516-524. doi: 10.1158/1055-9965.EPI-23-1272.
- DSouza G, Tewari S, Troy T, Bleyer P, Korley M, Kwait J, Ho K, Gillison M, Wiley D, Lazar J, Weber KM, Strickler H, Lahiri CD, Palella F, Struijk L, Fakhry C. Oral HPV incidence and risk factors for acquisition. Oral Oncol. 2025 Apr;163:107249. doi: 10.1016/j.oraloncology.2025.107249. Epub 2025 Mar 17.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Stomatognatiske sykdommer
- Patologiske prosesser
- Neoplasmer etter nettsted
- Neoplasmer
- Sykdomsattributter
- Infeksjoner
- Neoplasmer i hode og nakke
- Otorhinolaryngologiske sykdommer
- Faryngeale neoplasmer
- Otorhinolaryngologiske neoplasmer
- Faryngeale sykdommer
- Patologiske tilstander, tegn og symptomer
- Vedvarende infeksjon
- Orofaryngeale neoplasmer
Andre studie-ID-numre
Andre studie-ID-numre
- IRB00119537-2
- R56DE036518 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
The investigators will utilize a plan for the controlled release, management, and sharing of data. Data will be made available through a study research proposal process.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .